Selected article for: "death hospitalization and study objective"
Author: Singh, Ashima; Brandow, Amanda M.; Panepinto, Julie A.
Title: COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals
  • Cord-id: 2gadukcg
  • Document date: 2021_4_1
    • ID: 2gadukcg
    Snippet: In the United States, COVID-19 has disproportionately affected Black persons. Sickle cell disease (SCD) and sickle cell trait (SCT) are genetic conditions that occur predominantly among Black individuals. It is unknown if individuals with SCD/SCT are at higher risk of severe COVID-19 illness compared with Black individuals who do not have SCD/SCT. The objective of our study was to compare COVID-19 outcomes, including the disease manifestations, hospitalization, and death, among individuals with
    Document: In the United States, COVID-19 has disproportionately affected Black persons. Sickle cell disease (SCD) and sickle cell trait (SCT) are genetic conditions that occur predominantly among Black individuals. It is unknown if individuals with SCD/SCT are at higher risk of severe COVID-19 illness compared with Black individuals who do not have SCD/SCT. The objective of our study was to compare COVID-19 outcomes, including the disease manifestations, hospitalization, and death, among individuals with SCD/SCT vs Black individuals who do not have SCD/SCT. We leveraged electronic health record data from a multisite research network to identify Black patients with COVID-19 who have SCD/SCT and those who do not have SCD/SCT. During the study period of 20 January 2020 to 20 September 2020, there were 312 patients with COVID-19 and SCD and 449 patients with COVID-19 and SCT. There were 45 517 Black persons who were diagnosed with COVID-19 but who did not have SCD/SCT. After 1:1 propensity score matching (based on age, sex, and other preexisting comorbidities), patients with COVID-19 and SCD remained at a higher risk of hospitalization (relative risk [RR], 2.0; 95% CI, 1.5-2.7) and development of pneumonia (RR, 2.4; 95% CI, 1.6-3.4) and pain (RR, 3.4; 95% CI, 2.5-4.8) compared with Black persons without SCD/SCT. The case fatality rates for those with SCD compared with Black persons without SCD/SCT were not significantly different. There also were no significant differences in COVID-19 outcomes between individuals with SCT and Black persons without SCD/SCT within the matched cohorts.

    Search related documents:
    Co phrase search for related documents
    • acid amplification and additional risk: 1
    • acid amplification and liver disease: 1, 2
    • acid amplification and low proportion: 1
    • acid amplification and low sensitivity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute kidney failure and additional risk: 1
    • acute kidney failure and liver disease: 1, 2, 3, 4, 5, 6, 7, 8
    • acute organ dysfunction and additional risk: 1
    • acute organ dysfunction and liver disease: 1
    • acute pain and liver disease: 1, 2, 3, 4, 5
    • acute pain and low sensitivity: 1, 2
    • acute respiratory distress and additional risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory distress and liver condition: 1
    • acute respiratory distress and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45
    • acute respiratory distress and low proportion: 1, 2, 3, 4
    • acute respiratory distress and low sensitivity: 1, 2, 3, 4, 5, 6, 7
    • additional risk and liver condition: 1
    • additional risk and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • additional risk and low proportion: 1, 2
    • additional risk and low sensitivity: 1, 2